Spotlight on Oncology

Julie M. Vose, MD, MBA
Credits: 0.25 CME / CNE
Expert Insights: Current and Emerging CAR T-Cell and Other Cellular Therapies for the Treatment of Patients with Hematologic Malignancies
Julie M. Vose, MD, MBA
University of Nebraska Medical Center

Expert Insights: Current and Emerging CAR T-Cell and Other Cellular Therapies for the Treatment of Patients with Hematologic Malignancies

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit
0.25 ANCC contact hour
Released: November 1, 2021
Expires: November 1, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss the rationale for using cellular-based therapies for patients with hematologic malignancies
  • Evaluate the latest clinical trial data of current and emerging cellular therapies in patients with lymphoma and myeloma
  • Assess practical approaches to the use of cellular therapy, including patient referral and adverse event management strategies

Activity Description

Expert Insights is an interview involving two renowned experts actively engaged in treatment of patients with hematologic malignancies. This discussion features expert summary and interpretation of data presented at the August 11th satellite symposium during the 2021 Pan Pacific Lymphoma Conference.

Statement of Educational Need

CAR T-cell-based therapies have recently emerged as an option for the treatment of patients with hematologic malignancies. With recent approvals and emerging data from many clinical trials, oncologists must be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Clinicians require access to educational material that aids in evaluating emerging CAR T data and discusses the challenges of managing CAR T specific adverse events, to optimize clinical outcomes for patients with lymphoma and myeloma.

Faculty

Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska


Nina Shah, MD
Associate Professor, Department of Medicine
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Faculty
Julie M. Vose, MD, MBA
Advisory Committee/Board Member/Advisory Board: AbbVie; Acerta/AstraZeneca; Pharmacyclics
Consultant: MorphoSys

Nina Shah, MD
Research Funding: Celgene; Janssen; Bluebird Bio; Sutro Biopharma; Teneobio
Advisory Role: Genentech; Surface Oncology; Precision Biosciences; GSK; Nektar; Amgen; Indapta Therapeutics; Sanofi; Bristol Myers Squibb
Stock: Indapta Therapeutics

PlanningCommittee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
BioAscend: Jennifer Bechan, CMP, HMCC; Lucja Grajkowska, PhD; Kraig Steubing

Continuing Education

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Nebraska Medical Center designates this activity for up to 0.25 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Legend Biotech.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit
0.25 ANCC contact hour
Released: November 1, 2021
Expires: November 1, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss the rationale for using cellular-based therapies for patients with hematologic malignancies
  • Evaluate the latest clinical trial data of current and emerging cellular therapies in patients with lymphoma and myeloma
  • Assess practical approaches to the use of cellular therapy, including patient referral and adverse event management strategies

Activity Description

Expert Insights is an interview involving two renowned experts actively engaged in treatment of patients with hematologic malignancies. This discussion features expert summary and interpretation of data presented at the August 11th satellite symposium during the 2021 Pan Pacific Lymphoma Conference.

Statement of Educational Need

CAR T-cell-based therapies have recently emerged as an option for the treatment of patients with hematologic malignancies. With recent approvals and emerging data from many clinical trials, oncologists must be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Clinicians require access to educational material that aids in evaluating emerging CAR T data and discusses the challenges of managing CAR T specific adverse events, to optimize clinical outcomes for patients with lymphoma and myeloma.

Faculty

Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska


Nina Shah, MD
Associate Professor, Department of Medicine
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Faculty and Planning Committee Disclosures

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Faculty
Julie M. Vose, MD, MBA
Advisory Committee/Board Member/Advisory Board: AbbVie; Acerta/AstraZeneca; Pharmacyclics
Consultant: MorphoSys

Nina Shah, MD
Research Funding: Celgene; Janssen; Bluebird Bio; Sutro Biopharma; Teneobio
Advisory Role: Genentech; Surface Oncology; Precision Biosciences; GSK; Nektar; Amgen; Indapta Therapeutics; Sanofi; Bristol Myers Squibb
Stock: Indapta Therapeutics

PlanningCommittee
The following planning committee members have nothing to disclose:

UNMC: Brenda Ram, CMP, CHCP
BioAscend: Jennifer Bechan, CMP, HMCC; Lucja Grajkowska, PhD; Kraig Steubing

Continuing Education

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Nebraska Medical Center designates this activity for up to 0.25 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Legend Biotech.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Oncology Presentations

1.0 CME / CNE / CPE
Rush University Medical Center
Advances in Cervical Cancer: Addressing Unmet Needs in an Evolving Therapeutic Landscape

Advances in Cervical Cancer: Addressing Unmet Needs in an Evolving Therapeutic Landscape

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 14, 2022
Expires: July 13, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, gynecologic oncologists, oncology nurses, NPs/PAs, pharmacists and other healthcare professionals involved in the treatment of patients with cervical cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Assess clinical trial data of newly approved and emerging investigational agents for the treatment of recurrent or metastatic cervical cancer, and their potential role in the context of existing treatment paradigms
  • Integrate novel therapies into treatment plans for patients with recurrent or metastatic cervical cancer based on available guidelines, clinical trial data, and sequencing considerations
  • Identify and manage adverse events (AEs) associated with novel agents to promote adherence to therapy and optimize patient care
  • Incorporate multidisciplinary strategies into current clinical practice to provide best possible care of patients with recurrent or metastatic cervical cancer

Activity Description

This education activity is designed to provide the health-care team with the latest developments and critical insights into the treatment of recurrent or metastatic cervical cancer. This education will support the health-care professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

To provide optimal care to patients with recurrent or metastatic cervical cancer, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact patient outcomes. New and emerging therapies have significantly modified the treatment landscape in recurrent or metastatic cervical cancer. Due to the overwhelming amount of data that have been released in recent years, clinicians require education on the most relevant information, as well as identifying and managing treatment-related AEs, that will enable them to significantly enhance patient outcomes.

Faculty

Robert L. Coleman, M.D., FACOG, FACS
Gynecology/Oncology
US Oncology Research
Texas Oncology
Texas, United States

Disclosure
  • Scientific Steering Committee: AbbVie, AstraZeneca, Clovis Oncology, Genmab/Seagen, Immunogen, Janssen, Merck, Pfizer, Roche/Genentech, GSK, Deciphera, Zentalis, Alkermes, Agenus, Karyopharm, Mersana, Gradalis, Epsilogen
  • Research Funding: AstraZeneca, Abbvie, Clovis Oncology, Genmab/Seagen, Merck, Novartis, Roche/Genentech, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this Enduring Activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/ Physician Assistants/ Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this Enduring Activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Seagen and Genmab.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 14, 2022
Expires: July 13, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, gynecologic oncologists, oncology nurses, NPs/PAs, pharmacists and other healthcare professionals involved in the treatment of patients with cervical cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Assess clinical trial data of newly approved and emerging investigational agents for the treatment of recurrent or metastatic cervical cancer, and their potential role in the context of existing treatment paradigms
  • Integrate novel therapies into treatment plans for patients with recurrent or metastatic cervical cancer based on available guidelines, clinical trial data, and sequencing considerations
  • Identify and manage adverse events (AEs) associated with novel agents to promote adherence to therapy and optimize patient care
  • Incorporate multidisciplinary strategies into current clinical practice to provide best possible care of patients with recurrent or metastatic cervical cancer

Activity Description

This education activity is designed to provide the health-care team with the latest developments and critical insights into the treatment of recurrent or metastatic cervical cancer. This education will support the health-care professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

To provide optimal care to patients with recurrent or metastatic cervical cancer, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact patient outcomes. New and emerging therapies have significantly modified the treatment landscape in recurrent or metastatic cervical cancer. Due to the overwhelming amount of data that have been released in recent years, clinicians require education on the most relevant information, as well as identifying and managing treatment-related AEs, that will enable them to significantly enhance patient outcomes.

Faculty

Robert L. Coleman, M.D., FACOG, FACS
Gynecology/Oncology
US Oncology Research
Texas Oncology
Texas, United States

Disclosure
  • Scientific Steering Committee: AbbVie, AstraZeneca, Clovis Oncology, Genmab/Seagen, Immunogen, Janssen, Merck, Pfizer, Roche/Genentech, GSK, Deciphera, Zentalis, Alkermes, Agenus, Karyopharm, Mersana, Gradalis, Epsilogen
  • Research Funding: AstraZeneca, Abbvie, Clovis Oncology, Genmab/Seagen, Merck, Novartis, Roche/Genentech, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this Enduring Activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/ Physician Assistants/ Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this Enduring Activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Seagen and Genmab.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Martina C. Murphy, MD
1.0 CME
Integrity Continuing Education, Inc.
Contemporary Treatment of Endometrial Cancer: An In The Clinic Activity

Contemporary Treatment of Endometrial Cancer: An In The Clinic Activity

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 30, 2022
Expires: June 30, 2023
60 minutes to complete

Provided By

Integrity Continuing Education, Inc.

Statement of Commercial Support

This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.

Activity Description

The treatment options for advanced or recurrent endometrial cancer (EC) have changed dramatically in the last five years. Molecular testing to identify patients that could benefit from targeted treatments is now recommended for all patients. Choosing the optimal treatment can be complex as treatment planning must consider molecular signatures, safety and efficacy data, patient and tumor characteristics, and guideline recommendations.

In this edition of In the Clinic, Drs. Murphy and Westin will unpack the latest clinical trial data and review best practices for approaching treatment for these patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
  • Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
  • Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC

Faculty Co-Chairs

Martina C. Murphy, MD
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida

Martina C. Murphy, MD, does not have any real or apparent conflicts to disclose.


Shannon N. Westin, MD, MPH
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis

Case Development Faculty

Michaela Onstad-Grinsfelder, MD, MPH
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 30, 2022
Expires: June 30, 2023
60 minutes to complete

Provided By

Integrity Continuing Education, Inc.

Statement of Commercial Support

This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.

Activity Description

The treatment options for advanced or recurrent endometrial cancer (EC) have changed dramatically in the last five years. Molecular testing to identify patients that could benefit from targeted treatments is now recommended for all patients. Choosing the optimal treatment can be complex as treatment planning must consider molecular signatures, safety and efficacy data, patient and tumor characteristics, and guideline recommendations.

In this edition of In the Clinic, Drs. Murphy and Westin will unpack the latest clinical trial data and review best practices for approaching treatment for these patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
  • Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
  • Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC

Faculty Co-Chairs

Martina C. Murphy, MD
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida

Martina C. Murphy, MD, does not have any real or apparent conflicts to disclose.


Shannon N. Westin, MD, MPH
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis

Case Development Faculty

Michaela Onstad-Grinsfelder, MD, MPH
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

1.0 CME / CNE / CPE
Rush University Medical Center
Optimizing Care of Veterans with Advanced Renal Cell Carcinoma: Incorporating Immunotherapies and Targeted Agents into Clinical Practice

Optimizing Care of Veterans with Advanced Renal Cell Carcinoma: Incorporating Immunotherapies and Targeted Agents into Clinical Practice

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 16, 2022
Expires: June 15, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with renal cell carcinoma.

Learning Objectives

After completing this program, participants should be able to:

  • Analyze recent clinical trial data regarding the efficacy and safety of first-line immunotherapy-containing regimens for advanced renal cell carcinoma (RCC).
  • Identify and manage immune-related adverse events (irAEs) associated with immunotherapy-containing regimens.
  • Assess the appropriate roles for new therapies in the current treatment landscape of relapsed or refractory advanced RCC in the veteran population.
  • Integrate new therapeutic approaches into treatment plans for veterans with RCC within the VHA/MHS/DoD healthcare system.

Activity Description

This educational activity is designed to provide the healthcare team with the latest developments and critical insights into the management of advanced renal cell carcinoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application of available therapies.

Statement of Educational Need

The treatment paradigm for advanced RCC has evolved rapidly in recent years with the arrival of next-generation TKIs and combination approaches with immune checkpoint inhibitors. Despite these advancements, patients continue to exhibit inferior outcomes. To provide optimal patient care, clinicians require in-depth education surrounding these novel treatments, including the most recent clinical data regarding the efficacy and safety of these agents, current guideline recommendations, appropriate management of potential AEs, and approaches to select among available options and combinations in the first-line setting and beyond for patients with advanced RCC. Therefore, clinician education is urgently needed to improve outcomes for patients with RCC.

Faculty

Matthew Rettig, MD
Professor of Medicine and Urology
David Geffen School of Medicine at UCLA
Chief, Division of Hematology-Oncology, VA GLAHS
Los Angeles, CA

Disclosure
  • Research Grant: Novartis, Johnson & Johnson, Merck, Astellas, Medivation
  • Member, Speakers Bureau: J&J, Bayer
  • Consultant: Amgen, Ambryx, Clovis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Eisai, Exelixis, and Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 16, 2022
Expires: June 15, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with renal cell carcinoma.

Learning Objectives

After completing this program, participants should be able to:

  • Analyze recent clinical trial data regarding the efficacy and safety of first-line immunotherapy-containing regimens for advanced renal cell carcinoma (RCC).
  • Identify and manage immune-related adverse events (irAEs) associated with immunotherapy-containing regimens.
  • Assess the appropriate roles for new therapies in the current treatment landscape of relapsed or refractory advanced RCC in the veteran population.
  • Integrate new therapeutic approaches into treatment plans for veterans with RCC within the VHA/MHS/DoD healthcare system.

Activity Description

This educational activity is designed to provide the healthcare team with the latest developments and critical insights into the management of advanced renal cell carcinoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application of available therapies.

Statement of Educational Need

The treatment paradigm for advanced RCC has evolved rapidly in recent years with the arrival of next-generation TKIs and combination approaches with immune checkpoint inhibitors. Despite these advancements, patients continue to exhibit inferior outcomes. To provide optimal patient care, clinicians require in-depth education surrounding these novel treatments, including the most recent clinical data regarding the efficacy and safety of these agents, current guideline recommendations, appropriate management of potential AEs, and approaches to select among available options and combinations in the first-line setting and beyond for patients with advanced RCC. Therefore, clinician education is urgently needed to improve outcomes for patients with RCC.

Faculty

Matthew Rettig, MD
Professor of Medicine and Urology
David Geffen School of Medicine at UCLA
Chief, Division of Hematology-Oncology, VA GLAHS
Los Angeles, CA

Disclosure
  • Research Grant: Novartis, Johnson & Johnson, Merck, Astellas, Medivation
  • Member, Speakers Bureau: J&J, Bayer
  • Consultant: Amgen, Ambryx, Clovis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Eisai, Exelixis, and Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.0 CME
RMEI Medical Education, LLC
Seeing Nonmelanoma Skin Cancers Through a New Lens: The Role and Place of Immunotherapy: A Care Team Forum®

Seeing Nonmelanoma Skin Cancers Through a New Lens: The Role and Place of Immunotherapy: A Care Team Forum®

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: June 14, 2022
Expires: June 13, 2023
60 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncology and dermatology clinicians who manage patients with nonmelanoma skin cancer (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with difficult-to-treat nonmelanoma skin cancer (NMSC) based on current staging systems, risk factors, and guidelines
  • Select appropriate immunotherapy for advanced NMSC based on available data and approved indications

Activity Description

Join our multidisciplinary experts for an interactive program offering privileged insights into the evolving nonmelanoma skin cancer (NMSC) treatment paradigm. Core topics include evidence-based strategies for identifying patients at increased risk for disease progression, pinpointing the evolution of advanced disease, and integrating immunotherapy as a key component of the armamentarium against advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). A patient panelist augments these insights by highlighting aspects of their own treatment journey.

Chair

Prof. Axel Hauschild, MD
Professor, Dermatology
Head of Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany

Faculty

David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Mass General Cancer Center
Boston, United States


Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health Sciences
Washington DC, United States

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Prof. Axel Hauschild, MD, has relevant financial relationships with Amgen, BMS, Merck/Pfizer, MSD/Merck, Novartis, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme (Grant/Research Support).

David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Consultant); Checkpoint Therapeutics (Equity); Kartos Therapeutics, NeoImmune Tech, Inc, Regeneron (Research).

Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Almirall, Castle Biosciences, Regeneron, Sanofi (Speaker/Speaker’s Bureau); Jounce Therapeutics, PHD Biosciences, (Consultant); Almirall (Advisor); Lazarus AI, Science 37, Inc. (Stock/Shareholder).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: June 14, 2022
Expires: June 13, 2023
60 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncology and dermatology clinicians who manage patients with nonmelanoma skin cancer (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with difficult-to-treat nonmelanoma skin cancer (NMSC) based on current staging systems, risk factors, and guidelines
  • Select appropriate immunotherapy for advanced NMSC based on available data and approved indications

Activity Description

Join our multidisciplinary experts for an interactive program offering privileged insights into the evolving nonmelanoma skin cancer (NMSC) treatment paradigm. Core topics include evidence-based strategies for identifying patients at increased risk for disease progression, pinpointing the evolution of advanced disease, and integrating immunotherapy as a key component of the armamentarium against advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). A patient panelist augments these insights by highlighting aspects of their own treatment journey.

Chair

Prof. Axel Hauschild, MD
Professor, Dermatology
Head of Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany

Faculty

David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Mass General Cancer Center
Boston, United States


Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health Sciences
Washington DC, United States

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Prof. Axel Hauschild, MD, has relevant financial relationships with Amgen, BMS, Merck/Pfizer, MSD/Merck, Novartis, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme (Grant/Research Support).

David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Consultant); Checkpoint Therapeutics (Equity); Kartos Therapeutics, NeoImmune Tech, Inc, Regeneron (Research).

Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Almirall, Castle Biosciences, Regeneron, Sanofi (Speaker/Speaker’s Bureau); Jounce Therapeutics, PHD Biosciences, (Consultant); Almirall (Advisor); Lazarus AI, Science 37, Inc. (Stock/Shareholder).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

1.0 CME / CNE / CPE
Rush University Medical Center
The Evolving Treatment Landscape for Higher-Risk Myelodysplastic Syndrome

The Evolving Treatment Landscape for Higher-Risk Myelodysplastic Syndrome

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 3, 2022
Expires: June 2, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, hematologists/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with MDS.

Learning Objectives

After completing this program, participants should be able to:

  • Describe approaches for MDS diagnosis, classification, and risk stratification using hematologic, morphologic, clinical, and cytogenetic assessments
  • Outline available treatment approaches and associated outcomes for patients with MDS based on risk stratification, patient factors, clinical evidence, and available guidelines
  • Evaluate the clinical data regarding the efficacy and safety of emerging therapies for the treatment of patients with higher-risk MDS
  • Review factors that may impact consideration of clinical trial participation in patients with higher-risk MDS

Activity Description

Numerous new targeted therapies have emerged in recent years with early indications of benefit in patients with higher-risk MDS, particularly in combination with HMAs. These emerging options, which employ novel mechanisms of action and distinct molecular targets, may represent the first targeted therapies to improve outcomes in patients with higher-risk MDS. However, given the recent rapid emergence of data, clinicians are challenged to remain up to date on the latest evidence and the potential role of these therapies in the treatment landscape for patients with high-risk MDS. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application. Clinicians will hear up-to-date information on the latest evidence and the potential role of these therapies in the treatment landscape for patients with MDS.

Statement of Educational Need

With the recent advances in targeted therapies for higher-risk MDS, the use of investigational agents is anticipated to expand over the coming years. The introduction of these new agents and combinations into the clinic will likely change the therapeutic landscape for MDS and given the highly variable nature of the disease, will likely create uncertainty over differences in patients who may benefit, efficacy of emerging agents, optimal sequencing and combinations, and safety of the new agents and combinations. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with MDS, current evidence-based recommendations for the management of the disease, and the clinical utility of agents that could significantly impact patient outcomes.

Faculty

Jamile M. Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Director of MDS/MPN/Aplastic Anemia Program
Rush University Medical Center
Chicago, IL

Dr. Shammo has provided the following disclosure information:
  • Research Grant: AbbVie, Alexion, AstraZeneca, CTI, Incyte, Kartos, Stemline, BMS
  • Stockholder: AbbVie, Takeda, Baxter
  • Member, Speakers Bureau: Sanofi, Incyte, Alexion, BMS
  • Other: DSMB for NS Pharma and Apellis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from AbbVie, Gilead Sciences, Inc. and Novartis Pharmaceuticals Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 3, 2022
Expires: June 2, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, hematologists/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with MDS.

Learning Objectives

After completing this program, participants should be able to:

  • Describe approaches for MDS diagnosis, classification, and risk stratification using hematologic, morphologic, clinical, and cytogenetic assessments
  • Outline available treatment approaches and associated outcomes for patients with MDS based on risk stratification, patient factors, clinical evidence, and available guidelines
  • Evaluate the clinical data regarding the efficacy and safety of emerging therapies for the treatment of patients with higher-risk MDS
  • Review factors that may impact consideration of clinical trial participation in patients with higher-risk MDS

Activity Description

Numerous new targeted therapies have emerged in recent years with early indications of benefit in patients with higher-risk MDS, particularly in combination with HMAs. These emerging options, which employ novel mechanisms of action and distinct molecular targets, may represent the first targeted therapies to improve outcomes in patients with higher-risk MDS. However, given the recent rapid emergence of data, clinicians are challenged to remain up to date on the latest evidence and the potential role of these therapies in the treatment landscape for patients with high-risk MDS. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application. Clinicians will hear up-to-date information on the latest evidence and the potential role of these therapies in the treatment landscape for patients with MDS.

Statement of Educational Need

With the recent advances in targeted therapies for higher-risk MDS, the use of investigational agents is anticipated to expand over the coming years. The introduction of these new agents and combinations into the clinic will likely change the therapeutic landscape for MDS and given the highly variable nature of the disease, will likely create uncertainty over differences in patients who may benefit, efficacy of emerging agents, optimal sequencing and combinations, and safety of the new agents and combinations. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with MDS, current evidence-based recommendations for the management of the disease, and the clinical utility of agents that could significantly impact patient outcomes.

Faculty

Jamile M. Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Director of MDS/MPN/Aplastic Anemia Program
Rush University Medical Center
Chicago, IL

Dr. Shammo has provided the following disclosure information:
  • Research Grant: AbbVie, Alexion, AstraZeneca, CTI, Incyte, Kartos, Stemline, BMS
  • Stockholder: AbbVie, Takeda, Baxter
  • Member, Speakers Bureau: Sanofi, Incyte, Alexion, BMS
  • Other: DSMB for NS Pharma and Apellis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from AbbVie, Gilead Sciences, Inc. and Novartis Pharmaceuticals Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.0 CME / CNE / CPE
Rush University Medical Center
Management of Waldenström’s Macroglobulinemia in the Era of Targeted Therapies

Management of Waldenström’s Macroglobulinemia in the Era of Targeted Therapies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 13, 2022
Expires: May 12, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematologists, hematologists/oncologists, oncology nurses, NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  • Discuss the criteria for diagnosis and initiation of therapy for patients with Waldenström’s Macroglobulinemia, and use this information to guide initial workup and treatment decision-making
  • Assess the safety and efficacy of practice-changing clinical trial findings of current and emerging agents for Waldenström’s Macroglobulinemia
  • Integrate current guidelines, available clinical trial data, and real-world findings into individualized strategies for treatment selection, sequencing, and monitoring of Waldenström’s Macroglobulinemia

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The treatment of Waldenström’s Macroglobulinemia (WM) patients should be highly personalized, and the patient’s clinical presentation, comorbidities, genomic profile, and preferences, as well as toxicity of the treatment regimens, should be taken into account. Considering the continued evolution of therapeutic modalities and management strategies for WM and the information burden placed on busy community healthcare professionals who may have little to no experience with WM, expert guidance and interpretation of the clinical significance of emerging clinical data would benefit those caring for patients with WM, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Steven P. Treon, MD, MA, PhD
Professor of Medicine, Harvard Medical School
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Center
Boston, MA

Dr. Treon has provided the following disclosure information:
  • Research Support/P.I.: AbbVie/Pharmacyclics, Beigene, BMS, Eli Lilly
  • Consultant: Janssen, AbbVie/Pharmacyclics, Beigene, BMS

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Ascentage Pharma Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 13, 2022
Expires: May 12, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematologists, hematologists/oncologists, oncology nurses, NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  • Discuss the criteria for diagnosis and initiation of therapy for patients with Waldenström’s Macroglobulinemia, and use this information to guide initial workup and treatment decision-making
  • Assess the safety and efficacy of practice-changing clinical trial findings of current and emerging agents for Waldenström’s Macroglobulinemia
  • Integrate current guidelines, available clinical trial data, and real-world findings into individualized strategies for treatment selection, sequencing, and monitoring of Waldenström’s Macroglobulinemia

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The treatment of Waldenström’s Macroglobulinemia (WM) patients should be highly personalized, and the patient’s clinical presentation, comorbidities, genomic profile, and preferences, as well as toxicity of the treatment regimens, should be taken into account. Considering the continued evolution of therapeutic modalities and management strategies for WM and the information burden placed on busy community healthcare professionals who may have little to no experience with WM, expert guidance and interpretation of the clinical significance of emerging clinical data would benefit those caring for patients with WM, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Steven P. Treon, MD, MA, PhD
Professor of Medicine, Harvard Medical School
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Center
Boston, MA

Dr. Treon has provided the following disclosure information:
  • Research Support/P.I.: AbbVie/Pharmacyclics, Beigene, BMS, Eli Lilly
  • Consultant: Janssen, AbbVie/Pharmacyclics, Beigene, BMS

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Ascentage Pharma Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.25 CME / IPCE
RMEI Medical Education, LLC
Identifying Patients at Risk for Advanced NMSC: A Visual Guide

Identifying Patients at Risk for Advanced NMSC: A Visual Guide

Start

Activity Details

Free CME/IPCE
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
Released: April 27, 2022
Expires: April 26, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ established approaches for nonmelanoma skin cancer (NMSC) risk stratification and staging to identify patients at high risk for advanced or difficult-to-treat disease
  • Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by whiteboard animations and faculty videos to delineate risk factors for aggressive NMSC, risk stratification and staging methods, and the importance of interprofessional care.

Chair

Shailender Bhatia, MD
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Shailender Bhatia, MD, has relevant financial relationships with Bristol Myers Squibb, EMD Serono, Genentech, Regeneron, Sanofi Genzyme (Advisor); 4SC, Amphivena, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, Exicure, Immune Design, Merck, NantKwest, Nektar, Novartis, OncoSec, Xencor (Grant/Research Support paid to University of Washington).

All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/IPCE
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
Released: April 27, 2022
Expires: April 26, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ established approaches for nonmelanoma skin cancer (NMSC) risk stratification and staging to identify patients at high risk for advanced or difficult-to-treat disease
  • Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This 15-minute infographic activity uses an interactive approach augmented by whiteboard animations and faculty videos to delineate risk factors for aggressive NMSC, risk stratification and staging methods, and the importance of interprofessional care.

Chair

Shailender Bhatia, MD
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Shailender Bhatia, MD, has relevant financial relationships with Bristol Myers Squibb, EMD Serono, Genentech, Regeneron, Sanofi Genzyme (Advisor); 4SC, Amphivena, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, Exicure, Immune Design, Merck, NantKwest, Nektar, Novartis, OncoSec, Xencor (Grant/Research Support paid to University of Washington).

All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Matthew S. Davids, MD, MMSc
1.0 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives on Optimizing Outcomes with the Latest Advances in Small Molecule Inhibitors for Chronic Lymphocytic Leukemia

Expert Perspectives on Optimizing Outcomes with the Latest Advances in Small Molecule Inhibitors for Chronic Lymphocytic Leukemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: April 12, 2022
Expires: April 11, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Utilize testing for prognostic and predictive markers to stratify risk and optimize treatment selection for patients with CLL
  2. Employ the latest evidence and available guidelines to select among available therapeutic options in the first-line setting or for relapsed/refractory disease, including considerations for optimal sequencing of therapies
  3. Describe the clinical data regarding efficacy and safety of emerging therapies and approaches for the treatment of patients with CLL
  4. Outline acute and long-term safety considerations and factors influencing adherence to CLL treatment and evidence-based strategies to manage these considerations

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in targeted therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of new agents and combinations into the clinic have provided additional effective treatment options but have also created uncertainty over differences in patients who may benefit, efficacy of available and emerging agents, optimal sequencing and combinations, and safety among the available agents. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact outcomes for patients with CLL.

Faculty

Matthew S. Davids, MD, MMSc
Clinical Research Director, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Davids has provided the following disclosure information:
SAB/Consultant/Honoraria: AbbVie, BMS, Genentech, Janssen, Pharmacyclics, TG Therapeutics, Celgene, AstraZeneca, Eli Lilly, MEI Pharma, Merck, Adaptive Biosciences, BeiGene, Ascentage Pharma, Takeda, Aptitude Health, Research to Practice
Research funding: Genentech, Pharmacyclics, TG Therapeutics, MEI Pharma, Surface Oncology, AstraZeneca, Ascentage Pharma, Novartis


Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from AbbVie and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: April 12, 2022
Expires: April 11, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Utilize testing for prognostic and predictive markers to stratify risk and optimize treatment selection for patients with CLL
  2. Employ the latest evidence and available guidelines to select among available therapeutic options in the first-line setting or for relapsed/refractory disease, including considerations for optimal sequencing of therapies
  3. Describe the clinical data regarding efficacy and safety of emerging therapies and approaches for the treatment of patients with CLL
  4. Outline acute and long-term safety considerations and factors influencing adherence to CLL treatment and evidence-based strategies to manage these considerations

Activity Description

This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With the recent advances in targeted therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of new agents and combinations into the clinic have provided additional effective treatment options but have also created uncertainty over differences in patients who may benefit, efficacy of available and emerging agents, optimal sequencing and combinations, and safety among the available agents. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact outcomes for patients with CLL.

Faculty

Matthew S. Davids, MD, MMSc
Clinical Research Director, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Davids has provided the following disclosure information:
SAB/Consultant/Honoraria: AbbVie, BMS, Genentech, Janssen, Pharmacyclics, TG Therapeutics, Celgene, AstraZeneca, Eli Lilly, MEI Pharma, Merck, Adaptive Biosciences, BeiGene, Ascentage Pharma, Takeda, Aptitude Health, Research to Practice
Research funding: Genentech, Pharmacyclics, TG Therapeutics, MEI Pharma, Surface Oncology, AstraZeneca, Ascentage Pharma, Novartis


Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from AbbVie and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Shailender Bhatia, MD
0.25 CME / IPCE
RMEI Medical Education, LLC
Advanced NMSC: Determining Patient Candidacy for Immunotherapy

Advanced NMSC: Determining Patient Candidacy for Immunotherapy

Start

Activity Details

Free CME/IPCE
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
Released: April 6, 2022
Expires: April 5, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with advanced nonmelanoma skin cancer (NMSC) who are ideal candidates for treatment with immunotherapy
  • Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on assessing patient candidacy for immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). The discussion is augmented by case studies highlighting key aspects of risk stratification, staging, and management.

Chair

Shailender Bhatia, MD
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA

Faculty

Coley J. Doolittle-Amieva, MCMSc, PA-C
Physician Assistant, Seattle Cancer Care Alliance
Teaching Associate, University of Washington School of Medicine
Physician Assistant, UW Medicine
Seattle, WA


Emily S. Ruiz, MD, PhD
Academic Director, Mohs Dermatologic Surgery Center
Director, Dana Farber High Risk Cancer Clinic
Assistant Professor, Dermatology, Harvard Medical School
Department of Dermatology Brigham and Women's Faulkner Hospital
Boston, MA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Shailender Bhatia, MD, has relevant financial relationships with Bristol Myers Squibb, EMD Serono, Genentech, Regeneron, Sanofi Genzyme (Advisor); 4SC, Amphivena, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, Exicure, Immune Design, Merck, NantKwest, Nektar, Novartis, OncoSec, Xencor (Grant/Research Support paid to University of Washington).

Coley J. Doolittle-Amieva, MCMSc, PA-C, has no relevant financial relationships with ineligible companies to disclose.

Emily S. Ruiz, MD, PhD, has relevant financial relationships with Checkpoint Therapeutics, Leo Pharma, Pellepharma, Regeneron (Consultant).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/IPCE
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
Released: April 6, 2022
Expires: April 5, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with advanced nonmelanoma skin cancer (NMSC) who are ideal candidates for treatment with immunotherapy
  • Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on assessing patient candidacy for immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). The discussion is augmented by case studies highlighting key aspects of risk stratification, staging, and management.

Chair

Shailender Bhatia, MD
Director, Melanoma and Renal Cancer Team
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA

Faculty

Coley J. Doolittle-Amieva, MCMSc, PA-C
Physician Assistant, Seattle Cancer Care Alliance
Teaching Associate, University of Washington School of Medicine
Physician Assistant, UW Medicine
Seattle, WA


Emily S. Ruiz, MD, PhD
Academic Director, Mohs Dermatologic Surgery Center
Director, Dana Farber High Risk Cancer Clinic
Assistant Professor, Dermatology, Harvard Medical School
Department of Dermatology Brigham and Women's Faulkner Hospital
Boston, MA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Shailender Bhatia, MD, has relevant financial relationships with Bristol Myers Squibb, EMD Serono, Genentech, Regeneron, Sanofi Genzyme (Advisor); 4SC, Amphivena, Bristol Myers Squibb, Checkmate Pharmaceuticals, EMD Serono, Exicure, Immune Design, Merck, NantKwest, Nektar, Novartis, OncoSec, Xencor (Grant/Research Support paid to University of Washington).

Coley J. Doolittle-Amieva, MCMSc, PA-C, has no relevant financial relationships with ineligible companies to disclose.

Emily S. Ruiz, MD, PhD, has relevant financial relationships with Checkpoint Therapeutics, Leo Pharma, Pellepharma, Regeneron (Consultant).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Vishal Anil Patel, MD, FAAD, FACMS
0.25 CME / IPCE
RMEI Medical Education, LLC
Immunotherapy in Advanced NMSC: Treatment Selection and Collaborative Care

Immunotherapy in Advanced NMSC: Treatment Selection and Collaborative Care

Start

Activity Details

Free CME/IPCE
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
Released: April 6, 2022
Expires: April 5, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select appropriate immunotherapy for patients with advanced nonmelanoma skin cancer (NMSC) based on current safety and efficacy data
  • Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on evidence-based immunotherapy selection and collaborative care in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Chair

Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC

Faculty

David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA


Krista M. Rubin, MS, RN, FNP-BC
Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Lazarus AI, Science 37 (Stock/Shareholder); Regeneron, Sanofi (Speaker/Speaker’s Bureau); Almirall, Jounce Therapeutics, PhD Biosciences, Regeneron (Consultant); Almirall, Regeneron, Sanofi (Advisor).

David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Checkpoint Therapeutics (Stock/Shareholder); Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Advisory/Consultant); Kartos Therapeutics, NeoImmuneTech, Regeneron (Grants/Research Support).

Krista M. Rubin, MS, RN, FNP-BC, has relevant financial relationships with BMS, Eisai, Merck (Advisor).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/IPCE
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
Released: April 6, 2022
Expires: April 5, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select appropriate immunotherapy for patients with advanced nonmelanoma skin cancer (NMSC) based on current safety and efficacy data
  • Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on evidence-based immunotherapy selection and collaborative care in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Chair

Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC

Faculty

David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA


Krista M. Rubin, MS, RN, FNP-BC
Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Lazarus AI, Science 37 (Stock/Shareholder); Regeneron, Sanofi (Speaker/Speaker’s Bureau); Almirall, Jounce Therapeutics, PhD Biosciences, Regeneron (Consultant); Almirall, Regeneron, Sanofi (Advisor).

David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Checkpoint Therapeutics (Stock/Shareholder); Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Advisory/Consultant); Kartos Therapeutics, NeoImmuneTech, Regeneron (Grants/Research Support).

Krista M. Rubin, MS, RN, FNP-BC, has relevant financial relationships with BMS, Eisai, Merck (Advisor).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Pages